That is correct. Sanofi and Glaxo SmithKline Pharma have signed a pact to supply up to 60 million doses of a potential COVID-19 vaccine to the United Kingdom. This pertains to a vaccine candidate developed by Elf Sanofi of France in partnership with Britain’s Glaxo. The big challenge for pharma companies is to make COVID-19 vaccines affordable and available.

For UK, there is a sense of urgency as they need to secure early access to a wide range of vaccine candidates to increase chances of finding one that works. United Kingdom has the second highest number of COVID casualties in the world after the US. Britain already has access to 90 million doses of vaccines with BioNTech, Pfizer and Valneva.

The British government has also confirmed that it will purchase 100 million doses of the vaccine currently being tested by Oxford University in partnership with AstraZeneca.